Recent

% | $
Quotes you view appear here for quick access.

Cepheid Message Board

  • stellardad@pacbell.net stellardad Apr 4, 2014 12:36 PM Flag

    Cannacord Genuity says . . .

    $62. Also, if you recall, Cannacord was the first to call $54 when the price was in the 40's.

    Cepheid PT Raised to $62.00 at Canaccord Genuity (CPHD)
    Posted by Seth Barnet on Apr 3rd, 2014 // No Comments

    Cepheid (NASDAQ:CPHD) had its price target upped by Canaccord Genuity from $55.00 to $62.00 in a research note issued to investors on Wednesday, AR Network reports.

    Cepheid (NASDAQ:CPHD) opened at 52.79 on Wednesday. Cepheid has a one year low of $30.95 and a one year high of $55.89. The stock has a 50-day moving average of $53.21 and a 200-day moving average of $46.01. The company’s market cap is $3.664 billion.

    Cepheid (NASDAQ:CPHD) last posted its quarterly earnings results on Friday, January 31st. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.04. The company had revenue of $113.30 million for the quarter, compared to the consensus estimate of $102.17 million. Analysts expect that Cepheid will post $-0.24 EPS for the current fiscal year.

    Several other analysts have also recently commented on the stock. Analysts at Cowen and Company raised their price target on shares of Cepheid from $53.00 to $62.00 in a research note on Monday, March 10th. Separately, analysts at Jefferies Group raised their price target on shares of Cepheid from $36.00 to $43.00 in a research note on Friday, January 31st. Finally, analysts at Raymond James raised their price target on shares of Cepheid from $50.00 to $57.00 in a research note on Friday, January 31st. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $49.80.

    Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market

 
CPHD
28.01-0.24(-0.85%)May 31 4:00 PMEDT